PROPHASE LABS INC (PRPH) Stock Price, Quote, News and Overview
NASDAQ:PRPH - Nasdaq - US74345W1080 - Common Stock - Currency: USD
PRPH Quote, Performance and Key Statistics
0.2881
+0.01 (+2.75%)
The current stock price of PRPH is 0.2881 USD. In the past month the price decreased by -25.86%. In the past year, price decreased by -94.52%.
PRPH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
| JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 16.83 | 257.82B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
| MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
| PFE | PFIZER INC | 7.12 | 125.57B | ||
| SNY | SANOFI-ADR | 11.41 | 124.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
| GSK | GSK PLC-SPON ADR | 8.3 | 72.81B | ||
| ZTS | ZOETIS INC | 25.11 | 66.32B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.30B |
Related stock screener links
About PRPH
Company Profile
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 113 full-time employees. The firm provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Company Info
PROPHASE LABS INC
711 Stewart Ave, Suite 200, Garden City
New York City NEW YORK 11530 US
CEO: Ted Karkus
Employees: 113
Company Website: https://www.prophaselabs.com/
Investor Relations: http://www.prophaselabs.com/investors/annual-reports/
Phone: 12153450919
PROPHASE LABS INC / PRPH FAQ
What is the stock price of PROPHASE LABS INC today?
The current stock price of PRPH is 0.2881 USD. The price increased by 2.75% in the last trading session.
What is the ticker symbol for PROPHASE LABS INC stock?
The exchange symbol of PROPHASE LABS INC is PRPH and it is listed on the Nasdaq exchange.
On which exchange is PRPH stock listed?
PRPH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROPHASE LABS INC stock?
7 analysts have analysed PRPH and the average price target is 18.87 USD. This implies a price increase of 6449.81% is expected in the next year compared to the current price of 0.2881. Check the PROPHASE LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROPHASE LABS INC worth?
PROPHASE LABS INC (PRPH) has a market capitalization of 12.07M USD. This makes PRPH a Nano Cap stock.
How many employees does PROPHASE LABS INC have?
PROPHASE LABS INC (PRPH) currently has 113 employees.
What are the support and resistance levels for PROPHASE LABS INC (PRPH) stock?
PROPHASE LABS INC (PRPH) has a support level at 0.28 and a resistance level at 0.36. Check the full technical report for a detailed analysis of PRPH support and resistance levels.
Is PROPHASE LABS INC (PRPH) expected to grow?
The Revenue of PROPHASE LABS INC (PRPH) is expected to grow by 64.06% in the next year. Check the estimates tab for more information on the PRPH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROPHASE LABS INC (PRPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRPH, evaluating the profitability, health, valuation and growth aspects
- PROPHASE LABS INC (PRPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROPHASE LABS INC (PRPH) Sales and EPS estimates to see what analysts future expectations are.
- PROPHASE LABS INC (PRPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROPHASE LABS INC (PRPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROPHASE LABS INC (PRPH) Stock Chart to make your own analysis
- PROPHASE LABS INC (PRPH) Latest news and press-releases to stay up to date.
Does PROPHASE LABS INC (PRPH) stock pay dividends?
PRPH does not pay a dividend.
When does PROPHASE LABS INC (PRPH) report earnings?
PROPHASE LABS INC (PRPH) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of PROPHASE LABS INC (PRPH)?
PROPHASE LABS INC (PRPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.34).
What is the Short Interest ratio of PROPHASE LABS INC (PRPH) stock?
The outstanding short interest for PROPHASE LABS INC (PRPH) is 6.26% of its float. Check the ownership tab for more information on the PRPH short interest.
PRPH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRPH. When comparing the yearly performance of all stocks, PRPH is a bad performer in the overall market: 97.82% of all stocks are doing better.
PRPH Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PRPH. PRPH may be in some trouble as it scores bad on both profitability and health.
PRPH Financial Highlights
Over the last trailing twelve months PRPH reported a non-GAAP Earnings per Share(EPS) of -2.34. The EPS decreased by -138.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.23% | ||
| ROE | -72.8% | ||
| Debt/Equity | 0.29 |
PRPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PRPH. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 75.59% and a revenue growth 64.06% for PRPH